Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy

  • Zhao, Xuesong
  • Hao, Qianyun
  • Acosta, Daniel
  • Terán-Brage, Eduardo
  • Macarulla, Teresa
  • Alsina, Maria
  • Castet, Florian
  • Vega, kreina
  • Castro Boix, Sandra
  • TIAN, TIAN
Asia-West disparities; Chemotherapy; Gastric cancer, Disparidades entre Asia y Occidente; Quimioterapia; Cáncer gástrico, Disparitats entre Àsia i Occident; Quimioteràpia; Càncer gàstric, Gastric cancer (GC) remains a significant global health burden. Both Asian countries and Western nations, represented by Europe and North America, have long been pioneers in GC research and continue to lead advancements in the field. However, notable differences have historically existed between these regions in the treatment of resectable GC. In recent years, increasing convergence between Asian and Western approaches has emerged, driven by the growth of global collaborative studies. New definitive evidence suggests that the therapeutic landscape for resectable GC may undergo a significant transformation. In this review, we comprehensively examine the evolution of surgical approaches and perioperative chemotherapy strategies in Asia and the West. We summarize key clinical trials, highlight persistent survival disparities, and provide insight into current trends in perioperative management, including the recent advances in molecularly driven perioperative treatments. Finally, we outline key considerations for future multicenter perioperative trials to further guide global clinical practice., X.Z. is supported by grants from the Peking University People's Hospital (RDJP2024-20). T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation, and Universities (PID2023-146827OB-I00), the “Ramon y Cajal” program (RYC2020-029098-I), and the FERO Foundation. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis

  • Conti, Sefora
  • Basagana, Míriam
  • Pando Rau, Elizabeth
  • Caritá, Lorenzo
  • Villacampa Javierre, Guillermo
  • Tissera, Natalia Soledad
  • Castet, Florian
  • Salcedo, Maria-Teresa
  • DOPAZO, CRISTINA
  • Navarro Garces, Victor
  • TIAN, TIAN
  • Macarulla, Teresa
Anatomic location; Cholangiocarcinoma; Disease-free survival, Localització anatòmica; Colangiocarcinoma; Supervivència lliure de malaltia, Localización anatómica; Colangiocarcinoma; Supervivencia libre de enfermedad, Background & Aims Cholangiocarcinoma (CCA), a heterogeneous malignancy that includes intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes, often exhibits perineural invasion (PNI). Despite PNI being associated with postoperative recurrence, evidence on its prognostic impact remains inconsistent. To clarify this, we conducted a systematic review and meta-analysis. Methods A comprehensive literature search was conducted across the Medline-PubMed, Embase, and Web of Science databases from their inception through February 27, 2025. We included studies involving patients diagnosed with CCA who underwent surgery and for whom PNI data were available. The primary outcomes were overall survival (OS) and disease-free survival (DFS), extracted from both univariable and multivariable analyses. The study is registered in PROSPERO (CRD42024575458). Results Of 1,555 articles screened, 64 retrospective studies comprising 15,543 patients were included. In the univariable analysis, the pooled hazard ratio (HR) for OS from 34 studies (6,084 patients) was 1.92 (95% CI 1.67-2.21, I2 = 59.6%). Multivariable-adjusted analysis of 42 studies (10,335 patients) showed an HR of 1.68 (95% CI 1.47-1.90, I2 = 47.9%) for patients with PNI. For DFS, the pooled univariable HR in 6,110 patients was 1.70 (95% CI 1.46-1.98, I2 = 52.3%), and the multivariable HR was 1.62 (95% CI 1.37-1.92, I2 = 70.5%)). Prognostic consistency was observed across anatomical subgroups. Univariable OS HRs were 2.14 for iCCA, 1.69 for pCCA, and 1.66 for dCCA. Corresponding multivariable HRs were 1.74, 1.60, and 1.66, respectively. Conclusions PNI is a prognostic factor for both DFS and OS in CCA, regardless of anatomical location. Further research is needed to elucidate its biological mechanisms and potential therapeutic implications. Impact and implications This comprehensive review and meta-analysis confirms that perineural invasion (PNI) predicts poorer overall and disease-free survival in cholangiocarcinoma, independent of tumor location. These results highlight the potential of PNI as a reliable histopathological marker to stratify postoperative risk and inform patient management. While most evidence is retrospective and smaller studies may overstate the effect, the consistent findings emphasize the need for large, multicenter prospective studies with standardized pathological assessment. Such efforts could facilitate the integration of PNI into prognostic models and support more individualized treatment strategies for patients with cholangiocarcinoma., S.C. is supported by a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (JDC2023-050981-I). N.T. is supported by a La Pedrera MD-PhD fellowship from the Fundació Catalunya La Pedrera. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy

  • Zhao, Xuesong
  • Hao, Qianyun
  • Acosta, Daniel
  • Terán-Brage, Eduardo
  • Macarulla, Teresa
  • Alsina, Maria
  • Castet, Florian
  • Vega, kreina
  • Castro Boix, Sandra
  • TIAN, TIAN
Asia-West disparities; Chemotherapy; Gastric cancer, Disparidades entre Asia y Occidente; Quimioterapia; Cáncer gástrico, Disparitats entre Àsia i Occident; Quimioteràpia; Càncer gàstric, Gastric cancer (GC) remains a significant global health burden. Both Asian countries and Western nations, represented by Europe and North America, have long been pioneers in GC research and continue to lead advancements in the field. However, notable differences have historically existed between these regions in the treatment of resectable GC. In recent years, increasing convergence between Asian and Western approaches has emerged, driven by the growth of global collaborative studies. New definitive evidence suggests that the therapeutic landscape for resectable GC may undergo a significant transformation. In this review, we comprehensively examine the evolution of surgical approaches and perioperative chemotherapy strategies in Asia and the West. We summarize key clinical trials, highlight persistent survival disparities, and provide insight into current trends in perioperative management, including the recent advances in molecularly driven perioperative treatments. Finally, we outline key considerations for future multicenter perioperative trials to further guide global clinical practice., X.Z. is supported by grants from the Peking University People's Hospital (RDJP2024-20). T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation, and Universities (PID2023-146827OB-I00), the “Ramon y Cajal” program (RYC2020-029098-I), and the FERO Foundation. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis

  • Conti, Sefora
  • Basagana, Míriam
  • Pando Rau, Elizabeth
  • Caritá, Lorenzo
  • Villacampa Javierre, Guillermo
  • Tissera, Natalia Soledad
  • Castet, Florian
  • Salcedo, Maria-Teresa
  • DOPAZO, CRISTINA
  • Navarro Garces, Victor
  • TIAN, TIAN
  • Macarulla, Teresa
Anatomic location; Cholangiocarcinoma; Disease-free survival, Localització anatòmica; Colangiocarcinoma; Supervivència lliure de malaltia, Localización anatómica; Colangiocarcinoma; Supervivencia libre de enfermedad, Background & Aims Cholangiocarcinoma (CCA), a heterogeneous malignancy that includes intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes, often exhibits perineural invasion (PNI). Despite PNI being associated with postoperative recurrence, evidence on its prognostic impact remains inconsistent. To clarify this, we conducted a systematic review and meta-analysis. Methods A comprehensive literature search was conducted across the Medline-PubMed, Embase, and Web of Science databases from their inception through February 27, 2025. We included studies involving patients diagnosed with CCA who underwent surgery and for whom PNI data were available. The primary outcomes were overall survival (OS) and disease-free survival (DFS), extracted from both univariable and multivariable analyses. The study is registered in PROSPERO (CRD42024575458). Results Of 1,555 articles screened, 64 retrospective studies comprising 15,543 patients were included. In the univariable analysis, the pooled hazard ratio (HR) for OS from 34 studies (6,084 patients) was 1.92 (95% CI 1.67-2.21, I2 = 59.6%). Multivariable-adjusted analysis of 42 studies (10,335 patients) showed an HR of 1.68 (95% CI 1.47-1.90, I2 = 47.9%) for patients with PNI. For DFS, the pooled univariable HR in 6,110 patients was 1.70 (95% CI 1.46-1.98, I2 = 52.3%), and the multivariable HR was 1.62 (95% CI 1.37-1.92, I2 = 70.5%)). Prognostic consistency was observed across anatomical subgroups. Univariable OS HRs were 2.14 for iCCA, 1.69 for pCCA, and 1.66 for dCCA. Corresponding multivariable HRs were 1.74, 1.60, and 1.66, respectively. Conclusions PNI is a prognostic factor for both DFS and OS in CCA, regardless of anatomical location. Further research is needed to elucidate its biological mechanisms and potential therapeutic implications. Impact and implications This comprehensive review and meta-analysis confirms that perineural invasion (PNI) predicts poorer overall and disease-free survival in cholangiocarcinoma, independent of tumor location. These results highlight the potential of PNI as a reliable histopathological marker to stratify postoperative risk and inform patient management. While most evidence is retrospective and smaller studies may overstate the effect, the consistent findings emphasize the need for large, multicenter prospective studies with standardized pathological assessment. Such efforts could facilitate the integration of PNI into prognostic models and support more individualized treatment strategies for patients with cholangiocarcinoma., S.C. is supported by a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (JDC2023-050981-I). N.T. is supported by a La Pedrera MD-PhD fellowship from the Fundació Catalunya La Pedrera. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.